November 15, 2012 8:56 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical companydeveloping novel NNR Therapeutics ™, today announced that Stephen A. Hill,M.D. has been appointed as President and Chief Executive Officer. Dr. Hill isexpected to start with Targacept on December 1, 2012 and will also joinTargacept's Board of Directors.Dr. Hill brings over 20 years of industry experience to the role, havingserved previously as President and Chief Executive Officer of SolvayPharmaceuticals, Inc. and ArQule, Inc. At Solvay, he led an organization ofover 1,200 employees until its acquisition by Abbott Laboratories in 2010. Dr.Hill's responsibilities included the direct management of the U.S. commercialorganization and administrative support of U.S.-based clinical development,project management, quality, regulatory affairs and new business development.At ArQule, he led a successful transition from a fee-for-service discoverychemistry model to an enterprise with a proprietary clinical-stage pipeline.Prior to ArQule, Dr. Hill held several leadership positions with F.Hoffmann-La Roche Ltd., including Global Head of Clinical Development.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.